1
|
Wang J, Huang D, Chen H, Zhao Y. Biomimetic hepatic lobules from three-dimensional imprinted cell sheets. Sci Bull (Beijing) 2024:S2095-9273(24)00132-4. [PMID: 38490890 DOI: 10.1016/j.scib.2024.02.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 02/01/2024] [Accepted: 02/18/2024] [Indexed: 03/17/2024]
Abstract
Liver-tissue engineering has proven valuable in treating liver diseases, but the construction of liver tissues with high fidelity remains challenging. Here, we present a novel three-dimensional (3D)-imprinted cell-sheet strategy for the synchronous construction of biomimetic hepatic microtissues with high accuracy in terms of cell type, density, and distribution. To achieve this, the specific composition of hepatic cells in a normal human liver was determined using a spatial proteogenomics dataset. The data and biomimetic hepatic micro-tissues with hexagonal hollow cross-sections indicate that cell information was successfully generated using a homemade 3D-imprinted device for layer-by-layer imprinting and assembling the hepatic cell sheets. By infiltrating vascular endothelial cells into the hollow section of the assembly, biomimetic hepatic microtissues with vascularized channels for nutrient diffusion and drug perfusion can be obtained. We demonstrate that the resultant vascularized biomimetic hepatic micro-tissues can not only be integrated into a microfluidic drug-screening liver-on-a-chip but also assembled into an enlarged physiological structure to promote liver regeneration. We believe that our 3D-imprinted cell sheets strategy will open new avenues for biomimetic microtissue construction.
Collapse
Affiliation(s)
- Jinglin Wang
- Department of Hepatobiliary Surgery, Hepatobiliary Institute, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210008, China
| | - Danqing Huang
- Department of Hepatobiliary Surgery, Hepatobiliary Institute, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210008, China
| | - Hanxu Chen
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China
| | - Yuanjin Zhao
- Department of Hepatobiliary Surgery, Hepatobiliary Institute, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210008, China; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
| |
Collapse
|
2
|
Ma WL, Ma Y, Wang WH, Ding XC, Jiao Y, Liu SW, Hai L. [Analysis of the prognosis and survival of patients with acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:1051-1055. [PMID: 38016769 DOI: 10.3760/cma.j.cn501113-20230604-00243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Objective: To explore the influencing factors and the impact of artificial liver treatment on the prognosis and survival of patients with acute-on-chronic liver failure (ACLF). Methods: Clinical data from 201 cases with ACLF from January 2016 to December 2019 was retrospectively analyzed. The survival rate was calculated by the Kaplan-Meier method, the log-rank test of univariate analysis, and the multivariate analysis of the stepwise Cox regression forward method. Results: The median survival time of patients was 6 months, and the survival rates at 6, 9, and 12 months were 51.2%, 38.3%, and 29.9%, respectively. In univariate analysis, age, presence or absence of hypertension and upper gastrointestinal bleeding, treatment method, model for end-stage liver disease (MELD) score, and cholinesterase were associated with prognosis (P < 0.05). Multivariate regression analysis results showed that MELD score was the main factor affecting the 1-year prognosis of ACLF patients (P = 0.002). Artificial liver treatment was beneficial for the 1-year prognosis of ACLF patients aged < 50 years or with a MELD score of ≥20 (P < 0.05 ). The relative risk ratio (RR) of mortality was 2.55 times higher in patients with advanced age (≥50 years old) than that of younger patients (P < 0.001). Regression analysis was performed using age as a stratification factor, and upper gastrointestinal bleeding was related to the prognosis of younger patients, while choline esterase was related to the prognosis of advanced age. Regression analysis after stratified MELD score showed that age and hypertension were related to the prognosis of patients with MELD score < 20, and treatment method and age were related to the prognosis of patients with MELD score≥20. Conclusion: Artificial liver treatment is beneficial for the 1-year prognosis of ACLF patients. Age, MELD score, hypertension, and upper gastrointestinal bleeding are independent risk factors affecting the prognosis of ACLF patients.
Collapse
Affiliation(s)
- W L Ma
- Department of Infectious Diseases, Ningxia Medical University General Hospital, Yinchuan 750004, China
| | - Y Ma
- Department of Infectious Diseases, Ningxia Medical University General Hospital, Yinchuan 750004, China
| | - W H Wang
- Department of Nutrition, Ningxia Medical University General Hospital, Yinchuan 750004, China
| | - X C Ding
- Department of Infectious Diseases, Ningxia Medical University General Hospital, Yinchuan 750004, China
| | - Y Jiao
- Department of Infectious Diseases, Ningxia Medical University General Hospital, Yinchuan 750004, China
| | - S W Liu
- Department of Infectious Diseases, Ningxia Medical University General Hospital, Yinchuan 750004, China
| | - L Hai
- Department of Infectious Diseases, Ningxia Medical University General Hospital, Yinchuan 750004, China
| |
Collapse
|
3
|
Zhou X, Miu Y, Guo X, Wang J, Su T, Du H, Wang S, Zhang Y, Qiu Y, Zhao W. Observation on the Effect of Sequentially Combined Multi-modal Artificial Liver Treatment on HBV-related Acute-on-chronic Liver Failure. Curr Mol Med 2023:CMM-EPUB-134755. [PMID: 37807648 DOI: 10.2174/0115665240253035230920041207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 01/01/1970] [Accepted: 08/18/2023] [Indexed: 10/10/2023]
Abstract
OBJECTIVE To observe the short-term effect of sequentially combined multimodal artificial liver treatment (SCMALT) on HBV-related acute-on-chronic liver failure (HBV-ACLF). METHODS HBV-ACLF patients 155 cases undergoing artificial liver treatment were analyzed, and they were sorted into the SCMALT group and the conventional-modal artificial liver treatment (CALT) group. The clinical data of all patients were recorded and the serum levels of interleukin-8 (IL-8), chemokine interferon-inducible protein-10 (IP-10), and interleukin-6 (IL-6) were detected. The changes in the 30-day survival rate, cytokine level, model for end-stage liver disease (MELD) score, and complications of artificial liver treatment were analyzed. RESULTS After being followed up for 30 days, 104 patients survived and 51 died. At the end of the whole-course treatment, the decreases in IL-6, IP-10, and IL-8 levels and MELD scores in the SCMALT group were greater than in the CALT group. Cox regression suggested WBC (OR=1.066 , 95% CI 1.012-1.123 , P=0.017), AT-III activity (OR=0.935 , 95% CI 0.907-0.964 , P=0.000) at baseline, artificial liver treatment mode (OR=0.362,95% CI 0.164-0.800,P=0.012), number of artificial liver treatments (OR=0.656 , 95% CI 0.436-0.986 , P=0.043), spontaneous peritonitis (OR=0.337,95% CI 0.165-0.689,P=0.003), and hepatic encephalopathy (OR=0.104, 95% CI 0.028-0.388 , P=0.001) were independent influencing factors of 30-day survival rate. SCMALT can significantly prolong the survival period of the patient. No obvious difference was shown in the proportions of bleeding and circulation instability between the two groups (P>0.05). CONCLUSION Compared with the CALT, SCMALT can more effectively remove inflammatory mediators and reduce the MELD score in HBV-ACLF patients, which can obviously ameliorate the prognosis, with less effect on the platelet count.
Collapse
Affiliation(s)
- Xueshi Zhou
- Department of Infectious Disease, The First Affiliated Hospital of Soochow University, Suzhou Jiangsu 215000, China
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Youhan Miu
- Department of Infectious Disease, Nantong Third People's Hospital, Nantong University, Nantong Jiangsu 226000, China
| | - Xiaoye Guo
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Jun Wang
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Tingting Su
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Hejuan Du
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Sen Wang
- National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200000, China
| | - Ying Zhang
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Yuanwang Qiu
- Department of Infectious Disease ICU, Wuxi Fifth People's Hospital, Wuxi Jiangsu 214000, China
| | - Weifeng Zhao
- Department of Infectious Disease, The First Affiliated Hospital of Soochow University, Suzhou Jiangsu 215000, China
| |
Collapse
|
4
|
Han T, Liu GW. [Focusing on timing selection and whole-course management of liver transplantation treatment for patients with acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:561-563. [PMID: 37400377 DOI: 10.3760/cma.j.cn501113-20230303-00092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/05/2023]
Abstract
Acute-on-chronic liver failure (ACLF) is a clinical syndrome of acute decompensation accompanied by organ failure that occurs on the basis of chronic liver disease and has a high short-term mortality rate. Currently, there are still differences in relation to the definition of ACLF; thus, baseline characteristics and dynamic changes are important bases for clinical decision-making in patients with liver transplantation and others. The basic strategies for treating ACLF currently include internal medicine treatment, artificial liver support systems, and liver transplantation. Multidisciplinary active collaborative management throughout the whole course is of great significance for further improving the survival rate in patients with ACLF.
Collapse
Affiliation(s)
- T Han
- Department of Gastroenterology and Hepatology, Tianjin Union Medical Center Affiliated to Nankai University, Tianjin 300121, China
| | - G W Liu
- Department of Gastroenterology and Hepatology, Tianjin Union Medical Center Affiliated to Nankai University, Tianjin 300121, China
| |
Collapse
|
5
|
Antarianto RD, Mahmood A, Giselvania A, Asri Dewi AAP, Gustinanda J, Pawitan JA. Inventing Engineered Organoids for end-stage liver failure patients. J Mol Histol 2022; 53:611-621. [PMID: 35882727 PMCID: PMC9374785 DOI: 10.1007/s10735-022-10085-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 05/28/2022] [Indexed: 11/30/2022]
Abstract
End-stage liver disease (ESLD) is a term used clinically in reference to a group of liver diseases with liver transplantation as the choice of treatment. Due to the limitations of liver transplantation, alternative treatments are needed. The use of primary human hepatocytes represents a valid alternative treatment, but the limitations related to hepatocyte quality, viability, function, conservation, and storage need to be overcome. Transplanted hepatocytes have only been followed for 6–9 months. Therefore, long-term causes of failures are not yet established, including rejection, apoptosis, or other causes. Other alternative therapies to replace liver transplantation include plasmapheresis, hemodiafiltration, and artificial livers. Unfortunately, these methods are highly limited due to availability, high cost, anaphylaxis reaction, development-deposition of immune-complexes, and restricted functionality. Liver organoids, which utilize stem cells instead of ‘impractical’ adult hepatocytes, may be a solution for the development of a complex bioartificial liver. Recent studies have explored the benefits of differentiating mature hepatocytes from stem cells inside a bioreactor. When the use of human-induced Hepatocytes (hiHeps) was investigated in mouse and pig models of liver failure, liver failure markers were decreased, hepatocyte function indicated by albumin synthesis improved, and survival time increased. Bioartificial liver treatment may decrease the infiltration of inflammatory cells into liver tissue by down-regulating pro-inflammatory cytokines.
Collapse
Affiliation(s)
- Radiana D Antarianto
- Department of Histology Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Indonesia.
- Stem cell and tissue engineering research cluster IMERI UI, Jakarta, Indonesia.
| | - Amer Mahmood
- Stem Cell Unit, Department of Anatomy, King Saud University, Riyadh, Saudi Arabia
| | - Angela Giselvania
- Stem Cell Unit, Department of Anatomy, King Saud University, Riyadh, Saudi Arabia
- Department of Radiotherapy RS Cipto Mangunkusumo, Jakarta, Indonesia
| | - Ayu Aa Prima Asri Dewi
- Doctoral Program in Biomedical Science Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Indonesia
- Department of Histology, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Warmadewa, Bali, Indonesia
| | - Jatmiko Gustinanda
- Master Program in Biomedical Science Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Indonesia
| | - Jeanne Adiwinata Pawitan
- Department of Histology Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Indonesia
- Stem cell and tissue engineering research cluster IMERI UI, Jakarta, Indonesia
- Undergraduate Medicine Program Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Indonesia
- Integrated Service Unit Stem Cells RS Cipto Mangunkusumo, Jakarta, Indonesia
| |
Collapse
|
6
|
贾 金, 梁 菲, 黄 建, 王 昊, 韩 璞. [Effect of artificial liver with double plasma molecular absorb system model on patients' platelets and corresponding treatment strategy]. Beijing Da Xue Xue Bao Yi Xue Ban 2022; 54:548-551. [PMID: 35701134 PMCID: PMC9197708 DOI: 10.19723/j.issn.1671-167x.2022.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Indexed: 06/15/2023]
Abstract
OBJECTIVE To compare the effects of artificial liver treatment with double plasma molecular adsorption system(DPMAS) mode and traditional plasma exchange (PE) mode on platelets in patients, and to evaluate the clinical efficacy of recombinent human thrombopoietin (rhTPO) in the treatment of thrombocytopenia. METHODS A total of fifteen patients undergoing artificial liver with DPMAS model admitted to the Fifth Affiliated Hospital of Guangzhou Medical University from January 2018 to November 2020 were selected and included in the DPMAS group, and another 15 patients receiving PE were selected and included in the PE group. The improvement of clinical symptoms, such as fatigue, jaundice, oliguria, edema, etc. before and after artificial liver treatment was compared between the two groups, and the trend of blood routine (especially platelet), coagulation function and other indexes before and after treatment were compared between the two groups. The use of rhTPO and the number of platelets were recorded during treatment. RESULTS The improvement rate of clinical symptoms in DPMAS group was 86.67%, which was higher than that in PE group, but the difference was not statistically significant (P>0.05). There was no statistical significance in the outcome of the two groups within 90 days (P>0.05). There was no significant difference in white blood cell (WBC) and hemoglobin (HB) between the two groups after treatment (P>0.05). However, the level of platelet(PLT) in DPMAS group was significantly lower than that before treatment (P < 0.05), and was significantly lower than that in PE group (P < 0.05). After treatment, the international normalized ratio (INR) level in PE group was significantly improved (P < 0.05), but there was no significant difference in the INR level in DPMAS group (P>0.05). The patients in the DPMAS group received an average of (8.2±3.1) doses of rhTPO and (1.5±0.3) IU of platelet transfusions during hospitalization. In DMPAS group, platelets increased significantly after infusion of terbium. CONCLUSION Compared with PE mode, the artificial liver with DPMAS mode can reduce platelet levels in patients, but the application of rhTPO can stimulate platelet regeneration and increase platelet levels in the patients, thereby reducing the risk of bleeding due to platelet hypoplasia.
Collapse
Affiliation(s)
- 金凤 贾
- />广州医科大学附属第五医院消化内科, 广州 510700Department of Gastroenterology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| | - 菲 梁
- />广州医科大学附属第五医院消化内科, 广州 510700Department of Gastroenterology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| | - 建伟 黄
- />广州医科大学附属第五医院消化内科, 广州 510700Department of Gastroenterology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| | - 昊 王
- />广州医科大学附属第五医院消化内科, 广州 510700Department of Gastroenterology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| | - 璞青 韩
- />广州医科大学附属第五医院消化内科, 广州 510700Department of Gastroenterology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| |
Collapse
|
7
|
Li M, Wang X, Gong G, Tang Y, Zhang Y, Guo J, Liao X, Shi B. Natural polyphenol-based nanoengineering of collagen-constructed hemoperfusion adsorbent for the excretion of heavy metals. J Hazard Mater 2022; 428:128145. [PMID: 35007965 DOI: 10.1016/j.jhazmat.2021.128145] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 12/10/2021] [Accepted: 12/21/2021] [Indexed: 06/14/2023]
Abstract
Designing a hemoperfusion adsorbent for the excretion therapy of toxic heavy metals still remains a great challenge due to the biosafety risks of non-biological materials and the desired highly efficient removal capacity. Herein, inspired from the homeostasis mechanism of plants, natural polyphenols are integrated with collagen matrix to construct a polyphenol-functionalized collagen-based artificial liver (PAL) for heavy metals excretion and free radicals scavenging therapy. PAL presents high adsorption capacities for Cu2+, Pb2+, and UO22+ ions, up to 76.98 μmol g-1, 106.70 μmol g-1, and 252.48 μmol g-1, respectively. Remarkably, PAL possesses a high binding affinity for UO22+, Pb2+, and Cu2+ ions even in the complex serum environment with the presence of biologically-relevant ions (e.g., Mg2+, Ca2+ ions). Low hemolysis ratio (1.77%), high cell viability (> 85%), high plasma recalcification time (17.4 min), and low protein adsorption (1.02 μmol g-1) indicate outstanding biocompatibility of this material. This natural polyphenol/collagen-based fully bio-derived hemoperfusion adsorbent provides a novel and potentially applicable strategy for constructing a hemoperfusion adsorbent for heavy metal ions excretion therapy with efficiency and biosafety.
Collapse
Affiliation(s)
- Meifeng Li
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| | - Xiaoling Wang
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| | - Guidong Gong
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| | - Yi Tang
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| | - Yaoyao Zhang
- Key Laboratory of Birth Defects and Related of Women and Children of Ministry of Education, The Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China
| | - Junling Guo
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, Sichuan 610065, China; National Engineering Research Center of Clean Technology in Leather Industry, Sichuan University, Chengdu, Sichuan 610065, China.
| | - Xuepin Liao
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; National Engineering Research Center of Clean Technology in Leather Industry, Sichuan University, Chengdu, Sichuan 610065, China.
| | - Bi Shi
- Department of Biomass Chemistry and Engineering, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; BMI Center for Biomass Materials and Nanointerfaces, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China; State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, Sichuan 610065, China; National Engineering Research Center of Clean Technology in Leather Industry, Sichuan University, Chengdu, Sichuan 610065, China
| |
Collapse
|
8
|
Yang LH, Yang JH. [Prevention and treatment of infection after artificial liver treatment]. Zhonghua Gan Zang Bing Za Zhi 2020; 28:557-560. [PMID: 32791789 DOI: 10.3760/cma.j.cn501113-20200622-00340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Artificial liver support system is an important method of treating liver failure, but after artificial liver treatment, secondary infections are usually amalgamated. Additionally, infection is a risk factor that aggravates liver failure, leading to an increased mortality and poor prognosis. Therefore, how to prevent and treat occurrence of infection in patients with liver failure is a key factor to improve the efficacy of artificial liver treatment.
Collapse
Affiliation(s)
- L H Yang
- Department of Gastroenterology, the Second Affiliated Hospital, Kunming Medical University, Kunming 650033, China
| | - J H Yang
- Department of Gastroenterology, the Second Affiliated Hospital, Kunming Medical University, Kunming 650033, China
| |
Collapse
|
9
|
Qin S, Tang SH, Wang XH, Wang XP, Sun MY, Wu XL, Zeng WZ. [Value of serum alpha-fetoprotein for the prognostic evaluation of hepatitis B virus-related acute-on-chronic liver failure treated with artificial liver]. Zhonghua Gan Zang Bing Za Zhi 2020; 28:69-72. [PMID: 32023703 DOI: 10.3760/cma.j.issn.1007-3418.2020.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the value of alpha-fetoprotein (AFP) level on survived hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients treated with artificial liver. Methods: Clinical indicators of HBV-ACLF patients who were previously treated with plasma exchange-based artificial liver at our department were retrospectively collected. The difference of serum AFP level between the survival and the death group was compared at 30, 90 and 180 days after artificial liver treatment. The ROC curves of the subjects were plotted, and the sensitivity and specificity of AFP for the survival prediction of the patients at 30, 90 and 180 days after artificial liver surgery were calculated. AFP was divided into a high AFP group and a low AFP group using median value. AFP and postoperative survival predictive value at 30, 90, and 180 days were analyzed. Results: A total of 93 cases were included in this study. The AFP of the survival group at 30, 90, and 180 days was (231.0 ± 286.2) ng / ml, (237.69 ± 297) ng / ml, (229.44 ± 286.46) ng/ml, and the death group was (76.4 ± 104.7) ng/ml, (103.13 ± 116.99) ng / ml, (136.34 ± 2.9.29) ng/ml, respectively. AFP of the death group was significantly lower than the corresponding survival group (P < 0.05). Receiver operating characteristic (ROC) curve analyses indicated that the area under the curve (AUC) and its 95% confidence interval at 30, 90, and 180 days after artificial liver surgery were 0.739 (0.611 ~ 0.867), 0.675 (0.550 ~ 0.80), 0.653 (0.524 ~ 0.781), respectively. The median serum AFP value was 110 ng/ml, and the survival analysis showed that the survival time of the high AFP group was significantly higher than the low AFP group at 30 d (P = 0.01), 90 d (P = 0.04) and 180 d (P = 0.03) after artificial liver surgery. Conclusion: Serum AFP can be used as a predictor of survival for HBV-ACLF patients after artificial liver therapy and its clinical value needs to be further verified by the larger sample size.
Collapse
|
10
|
Abstract
End-stage liver failure is a condition of collapsing liver function with mortality rates up to 80. Liver transplantation is the only lifesaving therapy. There is an unmet need for therapy to extend the waiting time for liver transplantation or regeneration of the native liver. Here we review the state-of-the-art of non-cell based and cell-based artificial liver support systems, cell transplantation and plasma exchange, with the first therapy relying on detoxification, while the others aim to correct also other failing liver functions and/or modulate the immune response. Meta-analyses on the effect of non-cell based systems show contradictory outcomes for different types of albumin purification devices. For bioartificial livers proof of concept has been shown in animals with liver failure. However, large clinical trials with two different systems did not show a survival benefit. Two clinical trials with plasma exchange and one with transplantation of mesenchymal stem cells showed positive outcomes on survival. Detoxification therapies lack adequacy for most patients. Correction of additional liver functions, and also modulation of the immune system hold promise for future therapy of liver failure.
Collapse
Affiliation(s)
- Robert A F M Chamuleau
- Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, AG&M, Academic Medical Center, Meibergdreef 69-71, S1-176, 1105 BK, Amsterdam, The Netherlands.
| | - Ruurdtje Hoekstra
- Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, AG&M, Academic Medical Center, Meibergdreef 69-71, S1-176, 1105 BK, Amsterdam, The Netherlands
| |
Collapse
|
11
|
Minami T, Ishii T, Yasuchika K, Fukumitsu K, Ogiso S, Miyauchi Y, Kojima H, Kawai T, Yamaoka R, Oshima Y, Kawamoto H, Kotaka M, Yasuda K, Osafune K, Uemoto S. Novel hybrid three-dimensional artificial liver using human induced pluripotent stem cells and a rat decellularized liver scaffold. Regen Ther 2019; 10:127-133. [PMID: 31032388 PMCID: PMC6477477 DOI: 10.1016/j.reth.2019.03.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 03/07/2019] [Accepted: 03/14/2019] [Indexed: 12/14/2022] Open
Abstract
Introduction Liver transplantation is currently the only curative therapy for end-stage liver failure; however, establishment of alternative treatments is required owing to the serious donor organ shortage. Here, we propose a novel model of hybrid three-dimensional artificial livers using both human induced pluripotent stem cells (hiPSCs) and a rat decellularized liver serving as a scaffold. Methods Rat liver harvesting and decellularization were performed as reported in our previous studies. The decellularized liver scaffold was recellularized with hiPSC-derived hepatocyte-like cells (hiPSC-HLCs) through the biliary duct. The recellularized liver graft was continuously perfused with the culture medium using a pump at a flow rate of 0.5 mL/min in a standard CO2 (5%) cell incubator at 37 °C. Results After 48 h of continuous perfusion culture, the hiPSC-HLCs of the recellularized liver distributed into the parenchymal space. Furthermore, the recellularized liver expressed the albumin (ALB) and CYP3A4 genes, and secreted human ALB into the culture medium. Conclusion Novel hybrid artificial livers using hiPSCs and rat decellularized liver scaffolds were successfully generated, which possessed human hepatic functions. Human iPSC-derived hepatocytes were engrafted in a rat decellularized liver scaffold. The recellularized liver expressed human liver-related markers ALB and CYP3A4. The recellularized liver scaffold secreted human albumin. This novel model shows potential for artificial whole liver transplantation.
Collapse
Affiliation(s)
- Takahito Minami
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.,Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Takamichi Ishii
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Kentaro Yasuchika
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.,Japanese Red Cross Wakayama Medical Center, 4-20 Komatsubara-dori, Wakayama City 640-8558, Japan
| | - Ken Fukumitsu
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Satoshi Ogiso
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Yuya Miyauchi
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Hidenobu Kojima
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Takayuki Kawai
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Ryoya Yamaoka
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Yu Oshima
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Hiroshi Kawamoto
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Maki Kotaka
- Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Katsutaro Yasuda
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.,Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Kenji Osafune
- Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| | - Shinji Uemoto
- Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
| |
Collapse
|
12
|
Liver Failure and Artificial Liver Group; Chinese Society of Infectious Diseases; Chinese Medical Association. ; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. [Guideline for diagnosis and treatment of liver failure]. Zhonghua Gan Zang Bing Za Zhi. 2019;27:18-26. [PMID: 30685919 DOI: 10.3760/cma.j.issn.1007-3418.2019.01.006] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Liver failure is a familiar clinical severe liver disease syndrome with a very high mortality rate. Over the years, scholars from around the world have been exploring the definition, etiology, classification, types, diagnosis and treatment, and prognostic judgment of liver failure. Reflecting changes, that have transpired in recent years at home and abroad relevant to clinical evidence, this guideline updates the information previously published by the Chinese Society of Infectious Diseases, Chinese Medical Association, Liver Failure and Artificial Liver Group, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Guidelines for Diagnosis and Treatment of Liver Failure (2012 Edition).
Collapse
|
13
|
He GL, Feng L, Cai L, Zhou CJ, Cheng Y, Jiang ZS, Pan MX, Gao Y. Artificial liver support in pigs with acetaminophen-induced acute liver failure. World J Gastroenterol 2017; 23:3262-3268. [PMID: 28566885 PMCID: PMC5434431 DOI: 10.3748/wjg.v23.i18.3262] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 01/24/2017] [Accepted: 03/20/2017] [Indexed: 02/06/2023] Open
Abstract
AIM To establish a reversible porcine model of acute liver failure (ALF) and treat it with an artificial liver system.
METHODS Sixteen pigs weighing 30-35 kg were chosen and administered with acetaminophen (APAP) to induce ALF. ALF pigs were then randomly assigned to either an experimental group (n = 11), in which a treatment procedure was performed, or a control group (n = 5). Treatment was started 20 h after APAP administration and continued for 8 h. Clinical manifestations of all animals, including liver and kidney functions, serum biochemical parameters and survival times were analyzed.
RESULTS Twenty hours after APAP administration, the levels of serum aspartate aminotransferase, total bilirubin, creatinine and ammonia were significantly increased, while albumin levels were decreased (P < 0.05). Prothrombin time was found to be extended with progression of ALF. After continuous treatment for 8 h (at 28 h), aspartate aminotransferase, total bilirubin, creatinine, and ammonia showed a decrease in comparison with the control group (P < 0.05). A cross-section of livers revealed signs of vacuolar degeneration, nuclear fragmentation and dissolution. Concerning survival, porcine models in the treatment group survived for longer times with artificial liver system treatment (P < 0.05).
CONCLUSION This model is reproducible and allows for quantitative evaluation of new liver systems, such as a bioartificial liver. The artificial liver system (ZHJ-3) is safe and effective for the APAP-induced porcine ALF model.
Collapse
|
14
|
Sakiyama R, Blau BJ, Miki T. Clinical translation of bio artificial liver support systems with human pluripotent stem cell-derived hepatic cells. World J Gastroenterol 2017; 23:1974-1979. [PMID: 28373763 PMCID: PMC5360638 DOI: 10.3748/wjg.v23.i11.1974] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 12/02/2016] [Accepted: 01/11/2017] [Indexed: 02/06/2023] Open
Abstract
There is currently a pressing need for alternative therapies to liver transplantation. The number of patients waiting for a liver transplant is substantially higher than the number of transplantable donor livers, resulting in a long waiting time and a high waiting list mortality. An extracorporeal liver support system is one possible approach to overcome this problem. However, the ideal cell source for developing bioartificial liver (BAL) support systems has yet to be determined. Recent advancements in stem cell technology allow researchers to generate highly functional hepatocyte-like cells from human pluripotent stem cells (hPSCs). In this mini-review, we summarize previous clinical trials with different BAL systems, and discuss advantages of and potential obstacles to utilizing hPSC-derived hepatic cells in clinical-scale BAL systems.
Collapse
|
15
|
Li MQ, Ti JX, Zhu YH, Shi ZX, Xu JY, Lu B, Li JQ, Wang XM, Xu YJ. Combined use of non-biological artificial liver treatments for patients with acute liver failure complicated by multiple organ dysfunction syndrome. World J Emerg Med 2014; 5:214-7. [PMID: 25225587 PMCID: PMC4163812 DOI: 10.5847/wjem.j.issn.1920-8642.2014.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2014] [Accepted: 07/03/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Acute liver failure (ALF) caused by viral and non-viral hepatitis is often accompanied with severe metabolic disorders, the accumulation of toxic substances and continuous release and accumulation of a large number of endogenous toxins and inflammatory mediators. The present study aimed to investigate the effects of various combined non-biological artificial liver treatments for patients with acute liver failure (ALF) complicated by multiple organ dysfunction syndrome (MODS). METHODS Thirty-one patients with mid- or late-stage liver failure complicated by MODS (score 4) were randomly divided into three treatment groups: plasmapheresis (PE) combined with hemoperfusion (HP) and continuous venovenous hemodiafiltration (CVVHDF), PE+CVVHDF, and HP+CVVHDF, respectively. Heart rate (HR) before and after treatment, mean arterial pressure (MAP), respiratory index (PaO2/FiO2), hepatic function, platelet count, and blood coagulation were determined. RESULTS Significant improvement was observed in HR, MAP, PaO2/FiO2, total bilirubin (TBIL) and alanine aminotransferase (ALT) levels after treatment (P<0.05). TBIL and ALT decreased more significantly after treatment in the PE+CVVHDF and PE+HP+CVVHDF groups (P<0.01). Prothrombin time (PT) and albumin were significantly improved only in the PE+CVVHDF and PE+HP+CVVHDF groups (P<0.05). TBIL decreased more significantly in the PE+HP+CVVHDF group than in the HP+CVVHDF and PE+CVVHDF groups (P<0.05). The survival rate of the patients was 58.1% (18/31), viral survival rate 36.4% (4/11), and non-viral survival rate 70% (14/20). CONCLUSION Liver function was relatively improved after treatment, but PE+HP+CVVHDF was more efficient for the removal of toxic metabolites, especially bilirubin. The survival rate was significantly higher in the patients with non-viral liver failure than in those with viral liver failure.
Collapse
Affiliation(s)
- Mao-qin Li
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Jun-xiang Ti
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Yun-hang Zhu
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Zai-xiang Shi
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Ji-yuan Xu
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Bo Lu
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Jia-qiong Li
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Xiao-meng Wang
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| | - Yan-jun Xu
- Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China
| |
Collapse
|
16
|
Liu FH, He YK, Li QF, Wang SK. Comparative study of efficacy of different types of artificial liver treatments in management of hepatitis B-associated liver failure. Shijie Huaren Xiaohua Zazhi 2013; 21:1871-1876. [DOI: 10.11569/wcjd.v21.i19.1871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the clinical efficacy of plasma exchange (PE), plasma bilirubin adsorption (PBA), and PE combined with PBA in the treatment of hepatitis B-associated liver failure.
METHODS: The clinical data for 150 patients with hepatitis B-associated liver failure were retrospectively analyzed. These patients were randomly divided into a PE group, a PBA group, and a PE + PBA group. The volume of plasma consumed once, the effective rate, liver function, alanine aminotransferase (ALT), total bilirubin (TBIL), albumin (ALB), prothrombin time (PT), prothrombin time activity (PTA), creatinine (Cr) and plasma ammonia were recorded both before and after treatment and compared among the three groups. The incidence of adverse reactions was also observed.
RESULTS: The total effective rate was higher in the combination group than in the PE group and PBA group (65.45% vs 62.5%, 59.58%), but the difference was not statistically significant (both P > 0.05). TBIL was significantly decreased 4 hours after treatment compared to pre-treatment values in the PE, PBA and combination groups (410.3 µmol/L ± 208.6 µmol/L vs 292.5 µmol/L ± 175.4 µmol/L, 432.7 µmol/L ± 242.5 µmol/L vs 298.8 µmol/L ± 201.7 µmol/L, 468.2 µmol/L ± 241.6 µmol/L vs 288.5 µmol/L ± 184.5 µmol/L, all P < 0.05), but the decline showed no significantly statistical difference among the three groups. After treatment, PT was significantly shortened and PTA was increased in the combination group and PE group (both P < 0.05), but the changes showed no significant difference between the two groups (both P > 0.05). In the PBA group, PT was increased and PTA was decreased after treatment, but the differences were not significant (P > 0.05). Blood ammonia and Cr were significantly decreased in the three groups of patients after treatment (all P < 0.05), although there was no significantly statistical difference among the three groups. No serious adverse reactions occurred. The volume of plasma consumed once was significantly less in the combination group than in the PE group (1107.1 mL ± 212.3 mL vs 2911.5 mL ± 352.3 mL, P < 0.05).
CONCLUSION: PE combined with PBA can effectively reduce the amount of plasma consumed and the incidence of adverse reactions, improve survival and therefore represent a safe and effective treatment for hepatitis B-associated liver failure.
Collapse
|
17
|
Zhao HP, Hou TQ, Ding BH, Zhang ZR, Xing XJ, Zhi H, Shen XF. Therapeutic effect of plasma exchange combined with bilirubin absorption for hyperbilirubinemia: An analysis of 42 cases. Shijie Huaren Xiaohua Zazhi 2013; 21:629-632. [DOI: 10.11569/wcjd.v21.i7.629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To analyze the therapeutic effect of plasma exchange (PE) combined with bilirubin absorption (BA) in the treatment of hyperbilirubinemia.
METHODS: Forty-two patients with hyperbilirubinemia (55 events altogether) treated by PE combined with BA, including 28 males and 14 females, were enrolled. Their mean age was 52.14 years ± 8.52 years.
RESULTS: The overall response rate was 95.24% for the combination treatment group and 76.66% for the normal treatment group. There was a significant difference in the overall response rate between the two groups (P < 0.05). Both groups had a significant improvement in liver function after treatment. The combination treatment was more effective in the improvement of TBil and alkaline phosphatase (ALP) levels (both P < 0.05).
CONCLUSION: PE combined with BA is safe and effective in the treatment of hyperbilirubinemia.
Collapse
|
18
|
Abstract
Acute hepatic failure (AHF) is a devastating clinical syndrome characterized by rapid impairment of liver functions and development of encephalopathy, multiple organ failure, and in most cases cerebral edema. AHF has a high mortality rate. Although advances in drug treatment, artificial liver and liver transplantation have significantly improved the prognosis of AHF, there is still a lack of effective treatment for AHF because of its complicated etiopathogenesis, rapid progression and less clinical knowledge about managing the disease. There is an urgent need to develop effective treatments for AHF. This article aims to review recent advances in the treatment of AHF.
Collapse
|
19
|
Yang LX, Li XP, Zhang LL. Clinical effect of artificial liver combined with 131I therapy versus conventional medical treatment in patients with hyperthyroidism and severe liver injury: an analysis of 40 cases. Shijie Huaren Xiaohua Zazhi 2011; 19:2983-2986. [DOI: 10.11569/wcjd.v19.i28.2983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the clinical effect of artificial liver combined with 131I therapy versus conventional medical treatment in patients with hyperthyroidism and severe liver injury.
METHODS: The clinical data for 40 patients with hyperthyroidism and severe liver injury who were treated at our hospital over the past 6 years were retrospectively analyzed to compare the efficacy of artificial liver combined with 131I therapy versus conventional medical treatment.
RESULTS: Twenty-five patients underwent artificial liver treatment, and of them 20 had a response and 5 had disease progression. The response rate was 80%. Fifteen patients received conventional medical treatment, and of them 6 had a response and 59 had disease progression, with a response rate of only 40%. Artificial liver treatment significantly improved liver function and thyroid function, shortened PT time and increased the cure rate.
CONCLUSION: Artificial liver combined with 131I therapy can significantly improve prognosis and reduce mortality in patients with hyperthyroidism and severe liver injury.
Collapse
|
20
|
Kawazoe Y, Eguchi S, Sugiyama N, Kamohara Y, Fujioka H, Kanematsu T. Comparison between bioartificial and artificial liver for the treatment of acute liver failure in pigs. World J Gastroenterol 2006; 12:7503-7. [PMID: 17167841 PMCID: PMC4087598 DOI: 10.3748/wjg.v12.i46.7503] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To characterize and evaluate the therapeutic efficacy of bioartificial liver (BAL) as compared to that of continuous hemodiafiltration (CHDF) with plasma exchange (PE), which is the current standard therapy for fulminant hepatic failure (FHF) in Japan.
METHODS: Pigs with hepatic devascularization were divided into three groups: (1) a non-treatment group (NT; n = 4); (2) a BAL treatment group (BAL; n = 4), (3) a PE + CHDF treatment group using 1.5 L of normal porcine plasma with CHDF (PE + CHDF, n = 4). Our BAL system consisted of a hollow fiber module with 0.2 μm pores and 1 x 1010 of microcarrier-attached hepatocytes inoculated into the extra-fiber space. Each treatment was initiated 4 h after hepatic devascularization.
RESULTS: The pigs in the BAL and the PE + CHDF groups survived longer than those in the NT group. The elimination capacity of blood ammonia by both BAL and PE + CHDF was significantly higher than that in NT. Aromatic amino acids (AAA) were selectively eliminated by BAL, whereas both AAA and branched chain amino acids, which are beneficial for life, were eliminated by PE + CHDF. Electrolytes maintenance and acid-base balance were better in the CPE + CHDF group than that in the BAL group.
CONCLUSION: Our results suggest that PE + CHDF eliminate all factors regardless of benefits, whereas BAL selectively metabolizes toxic factors such as AAA. However since PE + CHDF maintain electrolytes and acid-base balance, a combination therapy of BAL plus CPE + CHDF might be more effective for FHF.
Collapse
Affiliation(s)
- Yasushi Kawazoe
- Department of Transplantation and Digestive Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
| | | | | | | | | | | |
Collapse
|
21
|
Yuan JZ, Ye QF, Zhao LL, Ming YZ, Sun H, Zhu SH, Huang ZF, Wang MM. Preoperative risk factor analysis in orthotopic liver transplant-ation with pretransplant artificial liver support therapy. World J Gastroenterol 2006; 12:5055-9. [PMID: 16937506 PMCID: PMC4087413 DOI: 10.3748/wjg.v12.i31.5055] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To assess the value of pre-transplant artificial liver support in reducing the pre-operative risk factors relating to early mortality after orthotopic liver transplantation (OLT).
METHODS: Fifty adult patients with various stages and various etiologies undergoing OLT procedures were treated with molecular adsorbent recycling system (MARS) as preoperative liver support therapy. The study included two parts, the first one is to evaluate the medical effectiveness of single MARS treatment with some clinical and laboratory parameters, which were supposed to be the therapeutical pre-transplant risk factors, the second part is to study the patients undergoing OLT using the regression analysis on preoperative risk factors relating to early mortality (30 d) after OLT.
RESULTS: In the 50 patients, the statistically significant improvement in the biochemical parameters was observed (pre-treatment and post-treatment). Eight patients avoided the scheduled Ltx due to significant relief of clinical condition or recovery of failing liver function, 8 patients died, 34 patients were successfully bridged to Ltx, the immediate outcome of this 34 patients within 30d observation was: 28 kept alive and 6 patients died.
CONCLUSION: Pre-operative SOFA, level of creatinine, INR, TNF-α, IL-10 are the main preoperative risk factors that cause early death after operation, MARS treatment before transplantion can relieve these factors significantly.
Collapse
Affiliation(s)
- Jin-Zhong Yuan
- Blood Purification Center, Xiangya Transplantation Institute, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
| | | | | | | | | | | | | | | |
Collapse
|